logo
logo

Iggenix Announces $25M In Series A1 Funding

Jul 27, 2021•almost 4 years ago

Amount Raised

$25 Million

Round Type

series a

San Francisco

Description

IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly address allergic disease, today announced that it has raised $25 million in an oversubscribed Series A1 financing. Khosla Ventures, which participated in IgGenix’s Series A funding in 2020, co-led the round along with Matthias Westman, a leading biotech investor and founding partner of Prosperity Capital Management. New investors include Alexandria Venture Investments, ShangBay Capital and AllerFund, the first and only venture capital firm focused on social impact in the food allergy space.

Company Information

Company

Ig Genix

Location

San Francisco, California, United States

About

IgGenix is a privately held biotechnology company taking a revolutionary approach to directly address food and other severe allergies by reengineering key antibodies involved in the allergic cascade. Founded based on research by professors Stephen Quake, Kari Nadeau, and Derek Croote of Stanford University, IgGenix isolates allergen-specific IgE antibodies and transforms them into IgG antibodies that alleviate and possibly prevent the allergic cascade. This novel approach may prevent life-threatening allergic reactions, saving lives and reducing the constant fear that affects people living with severe allergies. For more information, visit www.IgGenix.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech